A Post-Marketing Surveillance Study On Erbitux (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment.
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2012
At a glance
- Drugs Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 27 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2010 New trial record